JOP20190013A1 - أجسام مضادة لـ (تي آي ام -3) - Google Patents

أجسام مضادة لـ (تي آي ام -3)

Info

Publication number
JOP20190013A1
JOP20190013A1 JOP/2019/0013A JOP20190013A JOP20190013A1 JO P20190013 A1 JOP20190013 A1 JO P20190013A1 JO P20190013 A JOP20190013 A JO P20190013A JO P20190013 A1 JOP20190013 A1 JO P20190013A1
Authority
JO
Jordan
Prior art keywords
tim
antibodies
mucin
chemotherapy
domain
Prior art date
Application number
JOP/2019/0013A
Other languages
English (en)
Inventor
Zhang Yi
Carpenito Carmine
Shen Yang
Li Yiwen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of JOP20190013A1 publication Critical patent/JOP20190013A1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Abstract

يرتبط الاختراع الحالي بأجسام مضادة تربط بروتين -3 يحتوي على جلوبولين المناعي بالخلية التائية البشري ونطاق ميوسين (تي اي ام-3)، وقد تكون مفيدة لعلاج أورام الدم الصلبة بمفردها وفي توليفة مع المعالجة الكيميائية والإشعاع المؤين.
JOP/2019/0013A 2016-08-25 2017-06-16 أجسام مضادة لـ (تي آي ام -3) JOP20190013A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662379343P 2016-08-25 2016-08-25
US201762469753P 2017-03-10 2017-03-10

Publications (1)

Publication Number Publication Date
JOP20190013A1 true JOP20190013A1 (ar) 2019-01-31

Family

ID=59772703

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2019/0013A JOP20190013A1 (ar) 2016-08-25 2017-06-16 أجسام مضادة لـ (تي آي ام -3)

Country Status (26)

Country Link
US (1) US10253096B2 (ar)
EP (1) EP3504240B1 (ar)
JP (1) JP6502590B1 (ar)
KR (1) KR102142903B1 (ar)
CN (1) CN109563172B (ar)
AU (1) AU2017316473B2 (ar)
BR (1) BR112019001589A2 (ar)
CA (1) CA3035042A1 (ar)
CL (1) CL2019000488A1 (ar)
CO (1) CO2019001646A2 (ar)
CR (1) CR20190079A (ar)
DO (1) DOP2019000027A (ar)
EC (1) ECSP19013181A (ar)
ES (1) ES2908916T3 (ar)
IL (1) IL264159A (ar)
JO (1) JOP20190013A1 (ar)
MA (1) MA46041A (ar)
MX (1) MX2019002064A (ar)
PE (1) PE20190630A1 (ar)
PH (1) PH12019500369A1 (ar)
SG (1) SG11201900480YA (ar)
TN (1) TN2019000040A1 (ar)
TW (2) TWI639616B (ar)
UA (1) UA122929C2 (ar)
WO (1) WO2018039020A1 (ar)
ZA (1) ZA201900373B (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3274370T3 (da) 2015-03-23 2020-02-17 Bayer Pharma AG Anti-ceacam6-antistoffer og anvendelser deraf
PL3443009T3 (pl) 2016-04-12 2022-01-31 Symphogen A/S Przeciwciała i kompozycje anty-tim-3
CN109757103B (zh) 2016-07-14 2024-01-02 百时美施贵宝公司 针对tim3的抗体及其用途
CA3043761C (en) * 2016-12-08 2022-08-09 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
CA3185303A1 (en) 2017-04-05 2018-10-11 Symphogen A/S Combination therapies targeting pd-a, tim-3, and lag-3
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
CN111989341B (zh) 2018-04-12 2023-06-02 南京维立志博生物科技有限公司 结合tim-3的抗体及其用途
US20210261663A1 (en) * 2018-08-28 2021-08-26 Jiangsu Hengrui Medicine Co., Ltd. Anti-tim3 antibody pharmaceutical composition and use thereof
CA3117371A1 (en) * 2018-11-01 2020-05-07 Merck Patent Gmbh Methods of administering anti-tim-3 antibodies
CN113272017A (zh) * 2018-11-01 2021-08-17 默克专利有限公司 抗tim-3抗体
US20220089721A1 (en) 2018-12-19 2022-03-24 Bayer Aktiengesellschaft Pharmaceutical combination of anti ceacam6 and tim3 antibodies
KR20210102327A (ko) 2019-01-11 2021-08-19 일라이 릴리 앤드 캄파니 암 치료를 위한 tim-3 항체 및 다른 체크포인트 억제제와의 조합
US20220233691A1 (en) 2019-05-30 2022-07-28 Bristol-Myers Squibb Company Cell localization signature and combination therapy
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
EP3976832A1 (en) 2019-05-30 2022-04-06 Bristol-Myers Squibb Company Methods of identifying a subject suitable for an immuno-oncology (i-o) therapy
CN113164601B (zh) * 2019-09-19 2023-09-29 上药生物治疗（香港）有限公司 一种分离的抗原结合蛋白及其用途
MX2022008412A (es) 2020-01-07 2022-08-08 Univ Texas Variantes de enzima que agotan metiltioadenosina/adenosina mejorada humana para terapia de cancer.
MX2023002326A (es) 2020-08-31 2023-03-21 Bristol Myers Squibb Co Firma de localizacion celular e inmunoterapia.
WO2022120179A1 (en) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Multi-tumor gene signatures and uses thereof
EP4267172A1 (en) 2020-12-28 2023-11-01 Bristol-Myers Squibb Company Subcutaneous administration of pd1/pd-l1 antibodies
WO2022146947A1 (en) 2020-12-28 2022-07-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4314068A1 (en) 2021-04-02 2024-02-07 The Regents Of The University Of California Antibodies against cleaved cdcp1 and uses thereof
IL310773A (en) 2021-09-02 2024-04-01 Deutsches Krebsforschungszentrum Stiftung Des ?Ffentlichen Rechts Anti-CECAM6 antibodies with reduced side effects
WO2023178329A1 (en) 2022-03-18 2023-09-21 Bristol-Myers Squibb Company Methods of isolating polypeptides
WO2023235847A1 (en) 2022-06-02 2023-12-07 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709412B2 (en) 2001-06-29 2014-04-29 The Board Of Trustees Of The Leland Stanford Junior University Modulation of TIM receptor activity in combination with cytoreductive therapy
EP3020413A1 (en) 2002-01-30 2016-05-18 The Brigham and Women's Hospital, Inc. Compositions and methods related to TIM-3, a TH1-specific cell surface molecule
US8647623B2 (en) * 2009-04-10 2014-02-11 Kyowa Hakko Kirin Co., Ltd Method for treatment of blood tumor using anti-TIM-3 antibody
TWI629483B (zh) * 2010-06-11 2018-07-11 協和醱酵麒麟有限公司 anti-TIM-3 antibody
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2958643A1 (en) 2014-07-07 2016-01-14 Dana Farber Cancer Institute, Inc. Methods of treating cancer
US10259874B2 (en) * 2014-10-27 2019-04-16 Agency For Science, Technology And Research Anti-TIM-3 antibodies
GB201419094D0 (en) * 2014-10-27 2014-12-10 Agency Science Tech & Res Anti-TIM-3-antibodies
SI3215532T1 (sl) * 2014-11-06 2020-02-28 F. Hoffmann-La Roche Ag Protitelesa proti TIM3 in postopki uporabe
EP3218409A2 (en) * 2014-11-11 2017-09-20 Sutro Biopharma, Inc. Anti-pd-1 antibodies, compositions comprising anti-pd-1 antibodies and methods of using anti-pd-1 antibodies
CN104592388B (zh) * 2015-03-02 2017-05-31 中国人民解放军总医院 一种抗人Tim‑3的单克隆抗体的抗原结合部分
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
CA3043761C (en) * 2016-12-08 2022-08-09 Eli Lilly And Company Anti-tim-3 antibodies for combination with anti-pd-l1 antibodies
JOP20190133A1 (ar) * 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
JOP20190222A1 (ar) * 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
NZ749820A (en) 2021-05-28
IL264159A (en) 2019-02-28
CA3035042A1 (en) 2018-03-01
AU2017316473B2 (en) 2019-12-19
JP6502590B1 (ja) 2019-04-17
BR112019001589A2 (pt) 2019-07-09
ES2908916T3 (es) 2022-05-04
PE20190630A1 (es) 2019-04-26
JP2019517999A (ja) 2019-06-27
MX2019002064A (es) 2019-06-06
CN109563172B (zh) 2022-02-08
TWI639616B (zh) 2018-11-01
CO2019001646A2 (es) 2019-03-08
AU2017316473A1 (en) 2019-01-31
SG11201900480YA (en) 2019-02-27
US20180057591A1 (en) 2018-03-01
ZA201900373B (en) 2020-10-28
CL2019000488A1 (es) 2019-07-12
ECSP19013181A (es) 2019-03-29
KR102142903B1 (ko) 2020-08-11
TW201900684A (zh) 2019-01-01
US10253096B2 (en) 2019-04-09
TW201819419A (zh) 2018-06-01
EP3504240A1 (en) 2019-07-03
WO2018039020A1 (en) 2018-03-01
CN109563172A (zh) 2019-04-02
UA122929C2 (uk) 2021-01-20
TN2019000040A1 (en) 2020-07-15
DOP2019000027A (es) 2019-03-15
CR20190079A (es) 2019-04-08
PH12019500369A1 (en) 2019-11-25
MA46041A (fr) 2021-03-24
KR20190031528A (ko) 2019-03-26
EP3504240B1 (en) 2022-02-16

Similar Documents

Publication Publication Date Title
PH12019500369A1 (en) Anti-tim-3 antibodies
PH12019501253A1 (en) Anti-tim-3 antibodies for combination with anti-pd-1 antibodies
PH12020500225A1 (en) Anti- cd137 antibodies
MY199019A (en) Pd-1 antibodies
MY195110A (en) Antibodies to PD-1 and uses Thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
TN2018000044A1 (en) Pd-l1 ("programmed death-ligand 1") antibodies
MX2020006668A (es) Anticuerpos para lilrb2.
MX2022003718A (es) Anticuerpos que se unen a cd39 y sus usos.
MX2016006726A (es) Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer.
JO3567B1 (ar) جزيئات جسم مضاد لـ tim-3 واستخداماتها
MX2019015738A (es) Regimen de dosificacion para anticuerpos anti-tim-3 y usos de los mismos.
WO2018102589A3 (en) Anti-hrs antibodies and combination therapies for treating cancers
CR20210573A (es) Moléculas de unión a tigit y pd-1 / tigit
PH12019502313A1 (en) Anti-pd-l1-anti-tim-3 bispecific antibodies
MX2020009864A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-1.
MX2020009863A (es) Anticuerpos anti-cd137 para combinacion con anticuerpos anti-pd-l1.
EA201990258A1 (ru) Антитела к tim-3